FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.
A new treatment for rare, extreme hunger offers life-changing relief and uncovers clues to obesity’s tangled biology—reshaping how we understand and treat the condition.
A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.
The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
A controversial HHS document supporting RFK Jr.'s rollback of COVID vaccine guidance relies on disputed or misrepresented science, prompting outrage from health experts who call it “willful medical disinformation.”
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A Phase I study of intrathecal resiniferatoxin in patients with advanced cancer pain shows promising reductions in pain and opioid use, with durable effects and manageable side effects.